Header Logo

GEORGE R BLUMENSCHEIN

TitleProfessor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic?Targets. JTO Clin Res Rep. 2024 Feb; 5(2):100623. PMID: 38357092; PMCID: PMC10864847.
      Citations:    
    2. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292. PMID: 37311055; PMCID: PMC10712705.
      Citations:    Fields:    
    3. Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Target Oncol. 2023 Nov; 18(6):853-868. PMID: 37875771; PMCID: PMC10663259.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824. PMID: 37857711; PMCID: PMC10667103.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    5. Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081. PMID: 37728512; PMCID: PMC10566451.
      Citations:    Translation:Humans
    6. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881. PMID: 37478883; PMCID: PMC10529504.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    7. Aldea M, Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. PMID: 37068173.
      Citations: 3     Fields:    Translation:Humans
    8. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J, Le X. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 07; 11(7). PMID: 37402581; PMCID: PMC10335483.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    9. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep. 2023 Aug; 4(8):100533. PMID: 37649681; PMCID: PMC10462815.
      Citations: 1     
    10. Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693. PMID: 37129197.
      Citations:    Fields:    Translation:Humans
    11. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604. PMID: 36928818; PMCID: PMC10033402.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    12. Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851. PMID: 36898078; PMCID: PMC10414730.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    13. Villaruz LC, Blumenschein GR, Otterson GA, Leal TA. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. Cancer. 2023 05 01; 129(9):1319-1350. PMID: 36848319.
      Citations:    Fields:    Translation:Humans
    14. Molife C, Brnabic A, Stefaniak VJ, Belger MA, Gruver K, Chen JV, Souri S, Blumenschein GR. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. Immunotherapy. 2023 03; 15(4):293-309. PMID: 36748406.
      Citations:    Fields:    Translation:Humans
    15. Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2023 01; 29(1):104-114. PMID: 36624315; PMCID: PMC9873554.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    16. McQuade JL, Hammers H, Furberg H, Engert A, Andr? T, Blumenschein G, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol. 2023 01 01; 9(1):102-111. PMID: 36480191; PMCID: PMC9857666.
      Citations: 3     Fields:    Translation:Humans
    17. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Oct 29; 174:112-117. PMID: 36371941.
      Citations:    Fields:    
    18. Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol. 2022 10; 23(10):1321-1331. PMID: 36087590; PMCID: PMC10618956.
      Citations:    
    19. Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100391. PMID: 36089921; PMCID: PMC9449658.
      Citations:    
    20. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6. PMID: 35820397; PMCID: PMC9667883.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    21. Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR, Wang J. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20. PMID: 35443062.
      Citations:    Fields:    
    22. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970. PMID: 35413951; PMCID: PMC9005525.
      Citations: 1     Fields:    Translation:HumansCells
    23. Kindler HL, Novello S, Bearz A, Ceresoli GL, Aerts JGJV, Spicer J, Taylor P, Nackaerts K, Greystoke A, Jennens R, Burgers JA, Santoro A, Serwatowski P, Ponce S, Van Meerbeeck JP, Nowak AK, Blumenschein G, Siegel JM, Kasten L, Walter AO, Childs BH, Elbi C, Hassan R, Fennell DA, Calabr? L, Cedr?s S, K?chert K. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552. PMID: 35358455; PMCID: PMC10512125.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    24. Blumenschein G, Nagasaka M, Molife C, Cui ZL, Stefaniak V, Li X, Kim S, Lee HY, Beyrer J. Generalizability of ORIENT-11 trial results to a US?standard-of-care cohort with advanced non-small-cell lung cancer. Future Oncol. 2022 May; 18(16):1963-1977. PMID: 35354280.
      Citations:    Fields:    Translation:Humans
    25. Gillison ML, Blumenschein G, Fayette J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL, Guigay J, Rordorf T. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198. PMID: 35641218; PMCID: PMC8895496.
      Citations:    Fields:    Translation:Humans
    26. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022; 30:100514. PMID: 35051703; PMCID: PMC9259763.
      Citations:    Fields:    
    27. Blumenschein GR, Devarakonda S, Johnson M, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Frigault MJ, Olszanski AJ, Lam VK, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM, Moreno V, Doger de Sp?ville B. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer. J Immunother Cancer. 2022 01; 10(1). PMID: 35086946; PMCID: PMC8796260.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    28. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709. PMID: 34550757; PMCID: PMC8887948.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    29. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5. PMID: 34377884; PMCID: PMC8345916.
      Citations: 5     Fields:    Translation:Humans
    30. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591. PMID: 34241781.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    31. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67. PMID: 34237343.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    32. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514. PMID: 33603241; PMCID: PMC8818318.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    33. Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603. PMID: 33522021.
      Citations: 1     Fields:    Translation:Humans
    34. Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Granvil C, Skubala A, Genvresse I, Reschke S, Pe?a C, Mross K. Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020 Dec; 15(6):803. PMID: 33108585; PMCID: PMC7701068.
      Citations:    Fields:    
    35. Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2021 Feb; 76(2):155.e25-155.e34. PMID: 33268083.
      Citations: 3     Fields:    Translation:Humans
    36. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799. PMID: 33097651; PMCID: PMC7590373.
      Citations: 10     Translation:HumansCTClinical Trials
    37. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Leighl NB, Reynolds C, Blumenschein G, Gunuganti V, Li A, Aanur N, Spigel DR, Couture F. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020 11 20; 38(33):3863-3873. PMID: 32910710; PMCID: PMC7676888.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    38. Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors? Biol Blood Marrow Transplant. 2020 10; 26(10):1759-1769. PMID: 32623078.
      Citations: 4     Fields:    Translation:HumansCells
    39. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459. PMID: 32389639.
      Citations: 39     Fields:    Translation:Humans
    40. Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Granvil C, Skubala A, Genvresse I, Reschke S, Pe?a C, Mross K. Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020 04; 15(2):163-174. PMID: 32314268; PMCID: PMC7591420.
      Citations: 12     Fields:    
    41. Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol. 2020 06 01; 38(16):1824-1835. PMID: 32213105; PMCID: PMC7255978.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    42. Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ, Choy H. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 03 01; 38(7):706-714. PMID: 31841363; PMCID: PMC7048161.
      Citations: 86     Fields:    Translation:Humans
    43. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC, Hidalgo M. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476. PMID: 31853198; PMCID: PMC6916675.
      Citations: 32     
    44. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    45. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019 11; 14(11):1901-1911. PMID: 31446141; PMCID: PMC6823161.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    46. Saba NF, Blumenschein G, Licitra L, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Guigay J, Fayette J, Brossart P. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncol. 2019 09; 96:7-14. PMID: 31422216; PMCID: PMC7723820.
      Citations: 12     Fields:    Translation:Humans
    47. Haddad R, Concha-Benavente F, Blumenschein G, Fayette J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL, Guigay J. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218. PMID: 31246283; PMCID: PMC6771504.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    48. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML, Guigay J. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230. PMID: 31239321; PMCID: PMC7721346.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    49. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565. PMID: 31067138; PMCID: PMC6599408.
      Citations: 229     Fields:    Translation:HumansCTClinical Trials
    50. Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V, William WN. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477. PMID: 30596812; PMCID: PMC7360148.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    51. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031. PMID: 30780001.
      Citations: 35     Fields:    Translation:Humans
    52. Wheatley-Price P, Gadgeel S, Takahashi T, Li X, Dar M, Blumenschein GR. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 05; 20(3):e362-e368. PMID: 30685114.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    53. Gillison ML, Blumenschein G, Fayette J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL, Guigay J, Rordorf T. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082. PMID: 29866947; PMCID: PMC6221824.
      Citations: 23     Fields:    Translation:Humans
    54. Ferris RL, Blumenschein G, Fayette J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML, Guigay J, Rordorf T. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 06; 81:45-51. PMID: 29884413; PMCID: PMC6563923.
      Citations: 203     Fields:    Translation:Humans
    55. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Gettinger S, Holgado E, Spigel D, Waterhouse D, Garassino M, Chow LQM, Blumenschein G, Gainor J, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Ar?n Frontera O, Domine M, Barlesi F, Coudert B, Arrieta O, Crin? L. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965. PMID: 29408986.
      Citations: 174     Fields:    Translation:Humans
    56. Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 06 15; 24(12):2771-2779. PMID: 29563138; PMCID: PMC6004248.
      Citations: 45     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    57. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. Phase 1/2 Study of the Safety and Tolerability of?Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell?Lung Cancer (CheckMate 370). J Thorac Oncol. 2018 05; 13(5):682-688. PMID: 29518553.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    58. Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822. PMID: 29293386; PMCID: PMC6008104.
      Citations: 98     Fields:    Translation:Humans
    59. Reynolds KL, Bedard PL, Lee SH, Lin CC, Cohen E, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ, Tabernero J, Alsina M, Baselga J. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646. PMID: 28899363; PMCID: PMC5596462.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    60. Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Fayette J, Gr?nwald V, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115. PMID: 28651929; PMCID: PMC6461049.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    61. CheckMate 026 Investigators, Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 06 22; 376(25):2415-2426. PMID: 28636851; PMCID: PMC6487310.
      Citations: 960     Fields:    Translation:Humans
    62. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892. PMID: 28493811; PMCID: PMC5578390.
      Citations: 20     Fields:    Translation:Humans
    63. Gandara DR, Leighl N, Delord JP, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G, Barlesi F, Mazieres J. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced?Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. PMID: 27876675.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    64. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682. PMID: 27789196; PMCID: PMC5143183.
      Citations: 308     Fields:    Translation:HumansCTClinical Trials
    65. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867. PMID: 27718784; PMCID: PMC5564292.
      Citations: 1485     Fields:    Translation:HumansCTClinical Trials
    66. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802; PMCID: PMC5029622.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    67. Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Arrieta O, Burgio MA, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Blumenschein GR, Antonia SJ, Harbison CT, Graf Finckenstein F, Brahmer JR, Borghaei H, Kohlh?ufl M, Fayette J, Lena H, Crin? L, Dorange C. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22; 373(17):1627-39. PMID: 26412456; PMCID: PMC5705936.
      Citations: 3485     Fields:    Translation:HumansCTClinical Trials
    68. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24. PMID: 25968826; PMCID: PMC4432249.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    69. Juric D, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Roda D, Calles A, Jimeno A, Wang X, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Dienstmann R, Tabernero J, Boh?rquez SS, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2462-70. PMID: 26034219; PMCID: PMC5705193.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    70. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80. PMID: 26025965; PMCID: PMC4855241.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    71. Gomez DR, Liao KP, Swisher SG, Blumenschein GR, Erasmus JJ, Buchholz TA, Giordano SH, Smith BD. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiother Oncol. 2015 May; 115(2):257-63. PMID: 26013292.
      Citations: 40     Fields:    Translation:Humans
    72. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9. PMID: 24585506; PMCID: PMC5669372.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    73. Blumenschein GR, Smit EF, Planchard D, Kim DW, De Pas T, Dunphy F, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Cadranel J, Udud K, J?nne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)?. Ann Oncol. 2015 May; 26(5):894-901. PMID: 25722381; PMCID: PMC4855243.
      Citations: 130     Fields:    Translation:HumansCellsCTClinical Trials
    74. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99. PMID: 25601342; PMCID: PMC4419359.
      Citations: 621     Fields:    Translation:HumansCTClinical Trials
    75. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136; PMCID: PMC4253408.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    76. Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1. PMID: 25170013; PMCID: PMC4201000.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    77. Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6. PMID: 25042878; PMCID: PMC4169722.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    78. Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, Miller VA, Stephens PJ, Ross JS, Palmer GA, Janku F. Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. J Clin Oncol. 2016 Feb 10; 34(5):e34-7. PMID: 24934779.
      Citations: 5     Fields:    Translation:Humans
    79. Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM, Blumenschein GR. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906; PMCID: PMC3905243.
      Citations: 28     Fields:    Translation:Humans
    80. Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC, Spigel DR. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 10; 31(32):4105-14. PMID: 24101053; PMCID: PMC4878106.
      Citations: 200     Fields:    Translation:HumansCTClinical Trials
    81. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013 Oct; 13(5):378-84. PMID: 23810431; PMCID: PMC3839051.
      Citations: 17     Fields:    Translation:Humans
    82. Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol. 2013 09; 24(9):2382-9. PMID: 23788751; PMCID: PMC6267942.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    83. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298; PMCID: PMC5118909.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    84. Shepherd FA, Douillard JY, Blumenschein GR. [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. Zhongguo Fei Ai Za Zhi. 2013 Apr; 16(4):C9-20. PMID: 23601304; PMCID: PMC6123568.
      Citations:    Fields:    Translation:HumansCells
    85. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42. PMID: 23442309; PMCID: PMC3879952.
      Citations: 31     Fields:    Translation:Humans
    86. Gonzalez-Angulo AM, Blumenschein GR. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013 Jun; 39(4):313-20. PMID: 23218708; PMCID: PMC3604032.
      Citations: 40     Fields:    Translation:HumansCells
    87. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780; PMCID: PMC5161038.
      Citations: 8     Fields:    Translation:Humans
    88. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115; PMCID: PMC3567921.
      Citations: 463     Fields:    Translation:HumansAnimalsCells
    89. Blumenschein GR, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol. 2012 Sep; 7(9):1406-16. PMID: 22743295.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    90. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res. 2012 Sep; 1(3):179-93. PMID: 25806180; PMCID: PMC4367559.
      Citations: 18     
    91. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr; 31(2):417-24. PMID: 22918720; PMCID: PMC3589657.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    92. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan; 24(1):220-5. PMID: 22898037; PMCID: PMC3525135.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    93. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012 Sep 10; 30(26):3287-96. PMID: 22869872; PMCID: PMC3434988.
      Citations: 136     Fields:    Translation:HumansCells
    94. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15. PMID: 22736407; PMCID: PMC3461089.
      Citations: 28     Fields:    Translation:HumansCells
    95. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77. PMID: 22374333; PMCID: PMC3821167.
      Citations: 59     Fields:    Translation:HumansCells
    96. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021; PMCID: PMC3274509.
      Citations: 199     Fields:    Translation:HumansCells
    97. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol. 2011; 1:52. PMID: 22649768; PMCID: PMC3355954.
      Citations: 5     
    98. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    99. Blumenschein G. Insulin-like growth factor receptor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1799-800. PMID: 22005535.
      Citations: 1     Fields:    Translation:Humans
    100. Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep; 34(9):1255-62. PMID: 22009800; PMCID: PMC3893095.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    101. Blumenschein GR. Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs. 2012 Aug; 30(4):1802-11. PMID: 21987350.
      Citations: 4     Fields:    Translation:Humans
    102. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol. 2011 Oct; 6(10):1763-73. PMID: 21876456.
      Citations: 31     Fields:    Translation:Humans
    103. Belani CP, Goss G, Blumenschein G. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2012 May; 38(3):173-84. PMID: 21715100.
      Citations: 18     Fields:    Translation:HumansCells
    104. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319; PMCID: PMC4211116.
      Citations: 329     Fields:    Translation:HumansCTClinical Trials
    105. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8. PMID: 21555682; PMCID: PMC3107747.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    106. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun; 20(6):859-69. PMID: 21534718.
      Citations: 3     Fields:    Translation:HumansAnimals
    107. Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer. 2011 Jul; 12(4):212-7. PMID: 21726819.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    108. Blumenschein GR, Kabbinavar F, Menon H, Mok TSK, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L, Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep; 22(9):2057-2067. PMID: 21321086.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    109. Blumenschein GR, Reck M, Fossella F, Stewart DJ, Lathia C, Pe?a C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98. PMID: 22820084.
      Citations: 3     Fields:    Translation:Humans
    110. Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol. 2011 Sep; 68(3):703-12. PMID: 21140147; PMCID: PMC3400085.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    111. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15. PMID: 20855820; PMCID: PMC2974341.
      Citations: 90     Fields:    Translation:HumansCellsCTClinical Trials
    112. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    113. Ross HJ, Blumenschein GR, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010 Mar 15; 16(6):1938-49. PMID: 20215545.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    114. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505. PMID: 20094773.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    115. Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 01; 16(1):279-90. PMID: 20028752.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    116. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009 Sep 10; 27(26):4274-80. PMID: 19652055.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    117. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol. 2009 Aug; 127(8):1074-5. PMID: 19667357.
      Citations: 1     Fields:    Translation:Humans
    118. Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81. PMID: 19515503.
      Citations: 104     Fields:    Translation:Humans
    119. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009 May 20; 27(15):2516-22. PMID: 19380445.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    120. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S124-7. PMID: 18520294.
      Citations: 8     Fields:    Translation:Humans
    121. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12. PMID: 18520291.
      Citations: 2     Fields:    Translation:Humans
    122. Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008 Apr 10; 26(11):1879-85. PMID: 18398153.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    123. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol. 2008 Apr; 3(4):351-7. PMID: 18379352.
      Citations: 35     Fields:    Translation:Humans
    124. Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008 Mar; 47(3):276-9. PMID: 18289332.
      Citations: 16     Fields:    Translation:Humans
    125. Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007 Nov; 31(11):1645-52. PMID: 18059220.
      Citations: 65     Fields:    Translation:HumansCells
    126. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008 Feb; 26(1):81-7. PMID: 17960324.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    127. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85. PMID: 17418967.
      Citations: 3     Fields:    Translation:Humans
    128. Blumenschein G, Heymach JV. Angiogenesis inhibitors for lung cancer: clinical developments and future directions. J Thorac Oncol. 2006 Sep; 1(7):744-8. PMID: 17409952.
      Citations:    Fields:    Translation:Humans
    129. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4441s-4445s. PMID: 16857825.
      Citations: 23     Fields:    Translation:Humans
    130. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      Citations: 8     Fields:    Translation:Humans
    131. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7. PMID: 16342067.
      Citations: 25     Fields:    Translation:Humans
    132. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56. PMID: 16258975.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    133. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005 Dec 20; 23(36):9089-96. PMID: 16301597.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    134. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91. PMID: 15986399.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    135. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55. PMID: 15753462.
      Citations: 130     Fields:    Translation:HumansCTClinical Trials
    136. Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer. Cancer Biol Ther. 2004 Jul; 3(7):588-9. PMID: 15751163.
      Citations:    Fields:    Translation:Humans
    137. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14. PMID: 15184994.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    138. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77. PMID: 15050312.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    139. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23. PMID: 14601092.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    140. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21. PMID: 12886869.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    141. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5. PMID: 14596703.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    142. Blumenschein GR, Herbst RS. Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer. 2003 Jan; 4(4):217-23. PMID: 14624709.
      Citations:    Fields:    
    143. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53. PMID: 12124835.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    144. Esmaeli B, Naderi A, Hidaji L, Blumenschein G, Prieto VG. Merkel cell carcinoma of the eyelid with a positive sentinel node. Arch Ophthalmol. 2002 May; 120(5):646-8. PMID: 12003618.
      Citations: 5     Fields:    Translation:Humans
    145. Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, Drinkard L. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2633-7. PMID: 10068266.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    146. Dicke KA, Hood DL, Arneson M, Fulbright L, DiStefano A, Firstenberg B, Adams J, Blumenschein GR. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol. 1997 Jan; 25(1):34-8. PMID: 8989904.
      Citations: 2     Fields:    Translation:HumansCells
    147. Dicke KA, Hood DL, Hanks S, Vaughan M, Fulbright L, Dicke JA, Arneson M, Blumenschein G. A marrow harvest procedure under local anesthesia. Exp Hematol. 1995 Oct; 23(11):1229-32. PMID: 7556535.
      Citations: 1     Fields:    Translation:HumansCells
    148. Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother. 1992 Mar; 4(1):4-9. PMID: 1627272.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    149. Dillman RO, Oldham RK, Tauer KW, Orr DW, Barth NM, Blumenschein G, Arnold J, Birch R, West WH. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991 Jul; 9(7):1233-40. PMID: 2045864.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    150. Fraschini G, Yap HY, Mann G, Buzdar AU, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer. 1987 Oct 15; 60(8):1724-8. PMID: 3652000.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    151. Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer. 1987 Jun 15; 59(12):1992-9. PMID: 3567861.
      Citations: 3     Fields:    Translation:HumansCells
    152. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar; 5(3):354-64. PMID: 3819804.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    153. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb; 5(2):178-84. PMID: 3543241.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    154. Herring MK, Buzdar AU, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol. 1986 Jun; 9(3):269-75. PMID: 3755282.
      Citations: 6     Fields:    Translation:Humans
    155. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May; 46(5):2578-81. PMID: 3697997.
      Citations: 62     Fields:    Translation:Humans
    156. Casimir MT, Buzdar AU, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7. PMID: 3755230.
      Citations:    Fields:    Translation:Humans
    157. Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61. PMID: 3791560.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    158. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3. PMID: 3940620.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    159. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63. PMID: 3596041.
      Citations:    Fields:    Translation:Humans
    160. Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4. PMID: 4042070.
      Citations: 3     Fields:    Translation:Humans
    161. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer. 1985 Jul 15; 56(2):225-9. PMID: 4005794.
      Citations: 6     Fields:    Translation:Humans
    162. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985 Jun 15; 55(12):2761-5. PMID: 3922612.
      Citations: 79     Fields:    Translation:Humans
    163. Hug V, Rashid R, Blumenschein G, Spitzer G. Clonogenic in vitro growth and histologic grading of primary human breast tumors. Int J Cell Cloning. 1985 May; 3(3):143-8. PMID: 4008996.
      Citations: 2     Fields:    Translation:HumansCells
    164. Hug V, Burgess A, Blumenschein G, Hortobagyi G, Cohen AG. Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura. Cancer Treat Rep. 1985 May; 69(5):565-6. PMID: 4039981.
      Citations:    Fields:    Translation:Humans
    165. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41. PMID: 3841746.
      Citations: 3     Fields:    Translation:Humans
    166. Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning. 1985 Mar; 3(2):116-28. PMID: 3998518.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    167. Yau JC, Yap YY, Buzdar AU, Hortobagyi GN, Bodey GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer. 1985 Jan 15; 55(2):337-40. PMID: 3880657.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    168. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6. PMID: 3965092.
      Citations: 17     Fields:    Translation:Humans
    169. Feldman LD, Buzdar AU, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology. 1985; 42(5):273-4. PMID: 4034143.
      Citations:    Fields:    Translation:Humans
    170. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6. PMID: 3161565.
      Citations: 11     Fields:    Translation:Humans
    171. Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR, Montague ED. Induction chemotherapy of breast cancer. Prog Clin Biol Res. 1985; 201:105-16. PMID: 4095105.
      Citations:    Fields:    Translation:Humans
    172. Hug V, Drewinko B, Hortobagyi GN, Blumenschein G. Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Res Treat. 1985; 6(3):237-40. PMID: 4092099.
      Citations: 1     Fields:    Translation:HumansCells
    173. Buzdar AU, Blumenschein GR. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9. PMID: 6534512.
      Citations:    Fields:    Translation:Humans
    174. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61. PMID: 6548710.
      Citations: 3     Fields:    Translation:Humans
    175. Pinnamaneni K, Yap HY, Legha SS, Blumenschein GR, Bodey GP. Phase II study of spirogermanium in the treatment of metastatic breast cancer. Cancer Treat Rep. 1984 Sep; 68(9):1197-8. PMID: 6478457.
      Citations: 2     Fields:    Translation:Humans
    176. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31. PMID: 6385262.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    177. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug; 68(7-8):1039-41. PMID: 6547638.
      Citations: 2     Fields:    Translation:Humans
    178. Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol. 1984 Jul; 26(3):205-7. PMID: 6610802.
      Citations:    Fields:    Translation:Humans
    179. Finnerty NA, Buzdar AU, Blumenschein GR. Radiation-induced breast cancer. Arch Intern Med. 1984 Jun; 144(6):1217-9. PMID: 6732380.
      Citations: 1     Fields:    Translation:Humans
    180. Tannir N, Spitzer G, Dicke K, Schell F, DiStefano A, Blumenschein G. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep. 1984 May; 68(5):805-6. PMID: 6426793.
      Citations: 1     Fields:    Translation:Humans
    181. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40. PMID: 6231092.
      Citations: 1     Fields:    Translation:Humans
    182. Pinnamaneni K, Yap HY, Buzdar AU, Distefano A, Blumenschein GR. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4. PMID: 6546706.
      Citations: 1     Fields:    Translation:Humans
    183. Chawla SP, Buzdar AU, Hortobagyi GN, Blumenschein GR. Tumor-associated fever in breast cancer. Cancer. 1984 Apr 01; 53(7):1596-9. PMID: 6697296.
      Citations: 2     Fields:    Translation:Humans
    184. Hug V, Thames H, Blumenschein GR, Spitzer G, Drewinko B. Normalization of in vitro sensitivity testing of human tumor clonogenic cells. Cancer Res. 1984 Mar; 44(3):923-8. PMID: 6692414.
      Citations: 10     Fields:    Translation:HumansCells
    185. Buzdar AU, Blumenschein GR, Montague ED, Hortobagyi GN, Yap HY, Pinnamaneni K, Marcus CE, Smith TL. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984 Feb; 7(1):45-50. PMID: 6364779.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    186. Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984 Feb 01; 53(3):384-9. PMID: 6362814.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    187. Buzdar AU, Fraschini G, Blumenschein GR. Hematologic adverse effects of aminoglutethimide. Ann Intern Med. 1984 Jan; 100(1):159. PMID: 6691645.
      Citations: 3     Fields:    Translation:Humans
    188. Buzdar AU, Smith TL, Marcus CE, Hortobagyi GN, Blumenschein GR. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7. PMID: 6396767.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    189. Blumenschein GR, Buzdar AU, Hortobagyi GN. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res. 1984; 96:129-32. PMID: 6528087.
      Citations:    Fields:    Translation:Humans
    190. Hug V, Thames H, Johnston D, Blumenschein G, Drewinko B, Spitzer G. The true predictive value of the human tumor stem cell assay: does a workable assay select for treatment responders? J Clin Oncol. 1984 Jan; 2(1):42-5. PMID: 6699657.
      Citations: 1     Fields:    Translation:Humans
    191. Aboud A, Yap HY, Esparza L, Blumenschein GR, Hortobagyi G, Issell B, Bodey GP. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer. Cancer. 1984 Jan 01; 53(1):9-12. PMID: 6546298.
      Citations:    Fields:    Translation:Humans
    192. Yap HY, Esparza L, Blumenschein GR, Hortobagyi GN, Bodey GP. Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. Cancer Treat Rev. 1983 Dec; 10 Suppl B:53-5. PMID: 6661735.
      Citations: 4     Fields:    Translation:Humans
    193. Blumenschein GR. The role of progestins in the treatment of breast cancer. Semin Oncol. 1983 Dec; 10(4 Suppl 4):7-10. PMID: 6230722.
      Citations: 6     Fields:    Translation:HumansCells
    194. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86. PMID: 6668494.
      Citations: 34     Fields:    Translation:Humans
    195. Harkins LA, Yap HY, Buzdar AU, Blumenschein GR. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. Cancer. 1983 Oct 01; 52(7):1308-11. PMID: 6883292.
      Citations: 1     Fields:    Translation:Humans
    196. Hall SM, Buzdar AU, Blumenschein GR. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer. 1983 Jul 01; 52(1):180-4. PMID: 6850542.
      Citations: 7     Fields:    Translation:Humans
    197. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1983 Jun; 67(6):599-600. PMID: 6344995.
      Citations:    Fields:    Translation:Humans
    198. Hortobagyi GN, Spanos W, Montague ED, Buzdar AU, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 1983 May; 9(5):643-50. PMID: 6343312.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    199. DeMartini AL, Buzdar AU, Blumenschein GR. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. J Surg Oncol. 1983 May; 23(1):32-4. PMID: 6687746.
      Citations: 3     Fields:    Translation:Humans
    200. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6. PMID: 6834584.
      Citations: 11     Fields:    Translation:Humans
    201. Hortobagyi GN, Yap HY, Blumenschein GR, Buzdar AU, Barnes BC, Legha SS, Wiseman CL. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72. PMID: 6600415.
      Citations: 2     Fields:    Translation:Humans
    202. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8. PMID: 6687377.
      Citations: 31     Fields:    Translation:Humans
    203. Yap HY, Yap BS, Blumenschein GR, Barnes BC, Schell FC, Bodey GP. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar; 43(3):1402-4. PMID: 6825109.
      Citations: 10     Fields:    Translation:Humans
    204. Yap HY, Bedikian AY, Schell FC, Blumenschein GR, Bodey GP. Phase II clinical evaluation of AZQ in metastatic breast cancer. Am J Clin Oncol. 1983 Feb; 6(1):31-3. PMID: 6837505.
      Citations:    Fields:    Translation:Humans
    205. Yap HY, Valdivieso M, Blumenschein G, Hortobagyi G, Bedikian A. A phase I-II study of continuous 5-day infusion mitomycin-C. Am J Clin Oncol. 1983 Feb; 6(1):109-12. PMID: 6404154.
      Citations:    Fields:    Translation:Humans
    206. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40. PMID: 6824391.
      Citations: 12     Fields:    Translation:Humans
    207. Hug V, Spitzer G, Drewinko B, Blumenschein GR. Effect of diethylaminoethyl-dextran on colony formation of human tumor cells in semisolid suspension cultures. Cancer Res. 1983 Jan; 43(1):210-3. PMID: 6182989.
      Citations: 2     Fields:    Translation:HumansCells
    208. Stein W, Hortobagyi GN, Blumenschein GR. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol. 1983 Jan; 22(1):45-6. PMID: 6823117.
      Citations: 7     Fields:    Translation:Humans
    209. Buzdar AU, Powell KC, Legha SS, Blumenschein GR. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer. 1982 Nov 01; 50(9):1708-12. PMID: 6180820.
      Citations: 4     Fields:    Translation:Humans
    210. Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol. 1982 Oct; 5(5):511-4. PMID: 7180829.
      Citations: 1     Fields:    Translation:Humans
    211. Harvey HA, Lipton A, Lawrence BV, White DS, Wells SA, Blumenschein G, Lee D. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982 Sep; 21(1):42-4. PMID: 7109635.
      Citations: 5     Fields:    Translation:Humans
    212. Wiseman CL, Yap HY, Bedikian AY, Bodey GP, Blumenschein GR. Phase II trial of bruceantin in metastatic breast carcinoma. Am J Clin Oncol. 1982 Aug; 5(4):389-91. PMID: 7113961.
      Citations: 9     Fields:    Translation:Humans
    213. Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep. 1982 Aug; 66(8):1641-3. PMID: 7105054.
      Citations: 11     Fields:    Translation:Humans
    214. Buzdar AU, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug; 5(4):383-7. PMID: 6896794.
      Citations:    Fields:    Translation:Humans
    215. Buzdar AU, Powell KC, Blumenschein GR. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res. 1982 Aug; 42(8 Suppl):3448s-3450s. PMID: 7083209.
      Citations: 4     Fields:    Translation:Humans
    216. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982 Jul 15; 50(2):219-22. PMID: 6177395.
      Citations: 25     Fields:    Translation:Humans
    217. Yap BS, Yap HY, Blumenschein GR, Bedikian AY, Pocelinko R, Bodey GP. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene). Cancer Treat Rep. 1982 Jul; 66(7):1517-20. PMID: 7093967.
      Citations: 4     Fields:    Translation:Humans
    218. Raber MN, Barlogie B, Latreille J, Bedrossian C, Fritsche H, Blumenschein G. Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry. 1982 Jul; 3(1):36-41. PMID: 7117052.
      Citations: 22     Fields:    Translation:Humans
    219. Kavanagh JJ, Yap HY, Blumenschein GR, Stewart D, Bodey GP. Phase II trail of PCNU in refractory advanced breast cancer. Am J Clin Oncol. 1982 Jun; 5(3):249-51. PMID: 7081144.
      Citations: 2     Fields:    Translation:Humans
    220. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Freireich EJ. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982 May 01; 49(9):1762-6. PMID: 7074581.
      Citations: 17     Fields:    Translation:Humans
    221. Buzdar AU, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70. PMID: 7042074.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    222. Ross MB, Buzdar AU, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7. PMID: 6174195.
      Citations: 5     Fields:    Translation:Humans
    223. Zander AR, Spitzer G, Legha S, Dicke DA, Verma DS, Johnston DA, Vellekoop L, Beran M, Schell F, Minnhaar G, Blumenschein GR, Bodey GP. High-dose AMSA and bone marrow rescue in patients with solid tumors. Cancer Treat Rep. 1982 Feb; 66(2):385-6. PMID: 7034935.
      Citations: 2     Fields:    Translation:Humans
    224. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb; 96(2):133-9. PMID: 7059060.
      Citations: 138     Fields:    Translation:Humans
    225. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9. PMID: 6897369.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    226. Legha SS, Blumenschein GR. Systemic therapy of metastatic breast cancer: a review of the current trends. Oncology. 1982; 39(3):140-5. PMID: 7078937.
      Citations: 3     Fields:    Translation:Humans
    227. Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec; 95(6):694-7. PMID: 7305147.
      Citations: 29     Fields:    Translation:Humans
    228. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9. PMID: 7273012.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    229. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU, Blumenschein GR. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15; 48(2):227-32. PMID: 7237395.
      Citations: 4     Fields:    Translation:Humans
    230. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981 Jun 15; 47(12):2798-802. PMID: 7260870.
      Citations: 12     Fields:    Translation:Humans
    231. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981 Jun 15; 47(12):2803-6. PMID: 7260871.
      Citations: 10     Fields:    Translation:Humans
    232. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer. 1981 Jun 01; 47(11):2537-42. PMID: 6790155.
      Citations: 5     Fields:    Translation:Humans
    233. Richman SP, Hersh EM, Gutterman JU, Hortobagyi GN, Blumenschein GR, Rios A, Ribi E. Administration of BCG cell wall skeleton into malignant effusions: toxic and therapeutic effects. Cancer Treat Rep. 1981 May-Jun; 65(5-6):383-7. PMID: 7237463.
      Citations: 1     Fields:    Translation:Humans
    234. Yap HY, Blumenschein GR, Schell F, Bodey GP. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1981 May-Jun; 65(5-6):465-7. PMID: 7237467.
      Citations: 4     Fields:    Translation:HumansCells
    235. Hortobagyi GN, Smith TL, Swenerton KD, Legha SS, Buzdar AU, Blumenschein GR, Gutterman JU, Hersh EM. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76. PMID: 7226061.
      Citations: 3     Fields:    Translation:Humans
    236. Ho DH, Yap HY, Brown N, Benjamin RS, Friereich EJ, Blumenschein GR, Bodey GP. Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol. 1981 Feb-Mar; 21(2):72-8. PMID: 7229120.
      Citations: 6     Fields:    Translation:Humans
    237. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY, Schell FC, Barnes BC, Burgess MA. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72. PMID: 7300363.
      Citations: 1     Fields:    Translation:Humans
    238. DiStefano A, Yap HY, Blumenschein GR. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):33-8. PMID: 7013977.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    239. Wiseman CL, Tiber C, Blumenschein GR. Treatment of herniating subdural hematoma. JAMA. 1980 Dec 19; 244(24):2728-9. PMID: 7441857.
      Citations:    Fields:    Translation:Humans
    240. Yap BS, Yap HY, Fritsche HA, Blumenschein G, Bodey GP. CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. JAMA. 1980 Oct 03; 244(14):1601-3. PMID: 7420663.
      Citations: 11     Fields:    Translation:Humans
    241. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep; 93(3):399-406. PMID: 6159812.
      Citations: 98     Fields:    Translation:HumansCells
    242. Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45. PMID: 7397619.
      Citations: 2     Fields:    Translation:Humans
    243. Wiseman C, Cailleau R, Blumenschein GR, Bowen JM, Oliv? M. Autologous and homologous immunofluorescent antibody to established breast cancer cell lines. In Vitro. 1980 Jul; 16(7):629-33. PMID: 6997186.
      Citations:    Fields:    Translation:HumansCells
    244. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7. PMID: 7388758.
      Citations: 35     Fields:    Translation:Humans
    245. Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA, Bodey GP. A phase II study of peptichemio in advanced breast cancer. Cancer. 1980 May 15; 45(10):2524-8. PMID: 7378988.
      Citations: 5     Fields:    Translation:Humans
    246. Yap HY, Tashima CK, Blumenschein GR, Hortobagyi GN, Eckles N. Chemotherapy for advanced male breast cancer. JAMA. 1980 May 02; 243(17):1739-41. PMID: 7365938.
      Citations: 2     Fields:    Translation:Humans
    247. DiStefano A, Tashima CK, Fritsche HA, Geitner A, Cailleau R, Blumenschein GR. Carcinoembryonic antigen levels in malignant pleural fluids obtained from patients with mammary cancer. Am J Clin Pathol. 1980 Mar; 73(3):386-9. PMID: 7361717.
      Citations: 1     Fields:    Translation:Humans
    248. Wiseman CL, Bowen JM, Davis JW, Hersh EM, Brown BW, Blumenschein GR. Human lymphocyte blastogenesis responses to mouse mammary tumor virus. J Natl Cancer Inst. 1980 Mar; 64(3):425-30. PMID: 6243719.
      Citations: 1     Fields:    Translation:HumansCells
    249. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer. 1980 Feb 15; 45(4):742-9. PMID: 6986970.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    250. Krutchik AN, Buzdar AU, Akhtar M, Blumenschein GR. Immune-complex glomerulonephritis secondary to nonspecific immunotherapy. Cancer. 1980 Feb; 45(3):495-7. PMID: 6444365.
      Citations: 1     Fields:    Translation:HumansCells
    251. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):279-83. PMID: 7407762.
      Citations: 20     Fields:    Translation:Humans
    252. Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR. Pulmonary toxicity of mitomycin. Cancer. 1980 Jan 15; 45(2):236-44. PMID: 7351010.
      Citations: 5     Fields:    Translation:Humans
    253. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, Buzdar AU, Legha SS, Gutterman JU, Hersh EM, Bodey GP. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep. 1980 Jan; 64(1):157-9. PMID: 6991103.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    254. Benjamin RS, Hortobagyi GN, Swenerton KD, Blumenschein GR, Bodey GP. Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. Recent Results Cancer Res. 1980; 70:153-7. PMID: 7355246.
      Citations:    Fields:    Translation:Humans
    255. Yap HY, Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Krutchik AN, Benjamin RS, Gutterman JU, Bodey GP. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol. 1979 Dec; 12(4):333-41. PMID: 392197.
      Citations:    Fields:    Translation:Humans
    256. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979 Dec; 91(6):847-52. PMID: 517883.
      Citations: 15     Fields:    Translation:Humans
    257. Legha SS, Buzdar AU, Hortobagyi GN, DiStefano A, Wiseman CL, Yap HY, Blumenschein GR, Bodey GP. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2053-6. PMID: 118805.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    258. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979 Nov; 44(5):1913-8. PMID: 498057.
      Citations: 71     Fields:    Translation:Humans
    259. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1961-4. PMID: 526929.
      Citations: 7     Fields:    Translation:Humans
    260. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Nov; 44(5):1955-62. PMID: 387212.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    261. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979 Oct 05; 242(14):1509-13. PMID: 470088.
      Citations: 11     Fields:    Translation:Humans
    262. Yap HY, Tashima CK, Blumenschein GR, Eckles N. Diabetes insipidus and breast cancer. Arch Intern Med. 1979 Sep; 139(9):1009-11. PMID: 475518.
      Citations: 11     Fields:    Translation:Humans
    263. Yap HY, Tashima CK, Blumenschein GR, Eckles NE. Male breast cancer: a natural history study. Cancer. 1979 Aug; 44(2):748-54. PMID: 476581.
      Citations: 6     Fields:    Translation:Humans
    264. Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer. 1979 Aug; 44(2):398-405. PMID: 383255.
      Citations: 4     Fields:    Translation:Humans
    265. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52. PMID: 448865.
      Citations: 6     Fields:    Translation:Humans
    266. Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, Buzdar AU, Wiseman CL. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer. 1979 Jul; 44(1):32-4. PMID: 222433.
      Citations: 1     Fields:    Translation:Humans
    267. Buzdar AU, Legha SS, Hortobagyi GN, Blumenschein GR. Drug-associated cardiotoxicity. JAMA. 1979 May 04; 241(18):1893. PMID: 430767.
      Citations:    Fields:    Translation:Humans
    268. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May; 39(5):1552-62. PMID: 427797.
      Citations: 61     Fields:    Translation:Humans
    269. Yap HY, Murphy WK, DiStefano A, Blumenschein GR, Bodey GP. Phase II study of anguidine in advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):789-91. PMID: 455316.
      Citations: 5     Fields:    Translation:HumansAnimals
    270. Yap HY, Blumenschein GR, Yap BS, Hortobagyi GN, Tashima CK, Wang AY, Benjamin RS, Bodey GP. High-dose methotrexate for advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):757-61. PMID: 313246.
      Citations: 6     Fields:    Translation:Humans
    271. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Apr; 43(4):1225-33. PMID: 445325.
      Citations: 7     Fields:    Translation:Humans
    272. Hortobagyi GN, DiStefano A, Legha SS, Buzdar AU, Blumenschein GR. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep. 1979 Apr; 63(4):539-41. PMID: 221118.
      Citations:    Fields:    Translation:Humans
    273. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, Buzdar AU, Tashima CK, Burgess MA, Hersh EM. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer. 1979 Mar; 43(3):1112-22. PMID: 427716.
      Citations: 3     Fields:    Translation:Humans
    274. Ali MK, Soto A, Maroongroge D, Bekheit-Saad S, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Wiseman CL, Shullenberger CC. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979 Feb; 43(2):465-71. PMID: 421174.
      Citations: 6     Fields:    Translation:Humans
    275. Yap HY, Benjamin RS, Blumenschein GR, Hortobagyi GN, Tashima CK, Buzdar AU, Bodey GP. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):77-83. PMID: 369695.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    276. Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol. 1979; 12(1):27-40. PMID: 480951.
      Citations: 3     Fields:    Translation:Humans
    277. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):115-20. PMID: 369682.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    278. Legha SS, Benjamin RS, Buzdar AU, Hortobagyi GN, Blumenschein GR. Rubidazone in metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):135-6. PMID: 369685.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    279. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979; 11(4):325-32. PMID: 109703.
      Citations: 5     Fields:    Translation:Humans
    280. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu?rin. Cancer Treat Rep. 1978 Nov; 62(11):1685-92. PMID: 728894.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    281. Aldinger KA, Schultz PN, Blumenschein GR, Samaan NA. Thyroid-stimulating hormone and prolactin levels in breast cancer. Arch Intern Med. 1978 Nov; 138(11):1638-41. PMID: 102267.
      Citations: 7     Fields:    Translation:Humans
    282. Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM. Spontaneous regression of breast carcinoma. Arch Intern Med. 1978 Nov; 138(11):1734-5. PMID: 718333.
      Citations: 1     Fields:    Translation:Humans
    283. Krutchik AN, Buzdar AU, Blumenschein GR, Sinkovics JG. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep. 1978 Oct; 62(10):1565-7. PMID: 709557.
      Citations: 1     Fields:    Translation:Humans
    284. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80. PMID: 706354; PMCID: PMC1238308.
      Citations: 4     Fields:    Translation:Humans
    285. Krutchik AN, Buzdar A, Tashima CK, Blumenschein GR. Endobronchial metastasis from cancer of the breast. Chest. 1978 Sep; 74(3):319-20. PMID: 688798.
      Citations: 1     Fields:    Translation:Humans
    286. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. Arch Intern Med. 1978 Aug; 138(8):1302-3. PMID: 677992.
      Citations:    Fields:    Translation:Humans
    287. Buzdar AU, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN, Luna MA, Blumenschein GR. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep. 1978 Jul; 62(7):1005-8. PMID: 688243.
      Citations: 13     Fields:    Translation:Humans
    288. Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer. 1978 Jul; 42(1):283-6. PMID: 667799.
      Citations: 45     Fields:    Translation:Humans
    289. Samaan NA, deAsis DN, Buzdar AU, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978 Jun; 41(6):2084-7. PMID: 418867.
      Citations: 7     Fields:    Translation:Humans
    290. Krutchik AN, Blumenschein GR, Tashima CK, Buzdar AU. Cerebromedullospinal disconnection after intraventricular methotrexate. South Med J. 1978 Apr; 71(4):476-7. PMID: 635633.
      Citations:    Fields:    Translation:Humans
    291. Waterfield WC, Tashima CK, Hortobagyi GN, Blumenschein GR, Buzdar AU, Burgess MA. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer. 1978 Apr; 41(4):1235-9. PMID: 638989.
      Citations: 1     Fields:    Translation:Humans
    292. Tashima CK, Samaan NA, Blumenschein GR, Hickey RC. Etiologic factors of hypercalcemia in breast cancer. Tex Med. 1978 Mar; 74(3):52-5. PMID: 635813.
      Citations:    Fields:    Translation:Humans
    293. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer. 1978 Mar; 41(3):1064-75. PMID: 638948.
      Citations: 5     Fields:    Translation:Humans
    294. Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1978 Feb; 41(2):392-5. PMID: 630529.
      Citations: 3     Fields:    Translation:Humans
    295. Buzdar AV, Gutterman JU, Blumenschein GR, Tashima CK, Yap HY, Hersh EM, Gehan EA, Hortob?gyi GN. Adjuvant therapy of stage II, III breast cancer. Recent Results Cancer Res. 1978; 68:123-8. PMID: 379930.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    296. Legha SS, Hortobagyi G, Blumenschein GR. Therapy of advanced breast cancer. N Engl J Med. 1977 Dec 08; 297(23):1291-2. PMID: 917079.
      Citations:    Fields:    Translation:Humans
    297. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar A, Burgess MA, Richman SP, Tashima CK, Schwarz M, Hersh EM. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res. 1977; (62):143-50. PMID: 601328.
      Citations: 1     Fields:    Translation:Humans
    298. Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersh EM. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J. 1976 Nov 20; 2(6046):1222-5. PMID: 791447; PMCID: PMC1689748.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    299. Rodriguez V, Gottlieb J, Burgess MA, Livingston R, Wheeler W, Spitzer G, Bodey GP, Blumenschein GR, Freireich EJ. Phase I studies with Baker's Antifol (BAF) (NSC 139105). Cancer. 1976 Aug; 38(2):690-4. PMID: 974989.
      Citations: 4     Fields:    Translation:Humans
    300. Benjamin RS, Hall SW, Burgess MA, Wheeler WL, Murphy WK, Blumenschein GR, Gottlieb JA. A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC-3053). Cancer Treat Rep. 1976 Mar; 60(3):289-91. PMID: 1260785.
      Citations: 4     Fields:    Translation:HumansAnimals
    301. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976 Feb; 60(2):199-203. PMID: 769974.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    302. Shambaugh GE, Blumenschein GR. Combined effects of phytohemagglutinin and staphylococcal enterotoxin B on deoxyribonucleic acid synthesis during blast transformation in human lymphocytes. Infect Immun. 1974 Feb; 9(2):384-90. PMID: 4361297; PMCID: PMC414813.
      Citations: 1     Fields:    Translation:HumansCells
    303. Hickey RC, Blumenschein GR, McHardy G, Hightower NC. Telephone consultation--dial access: a project in cancer education and control. South Med J. 1973 Oct; 66(10):1159-62. PMID: 4745102.
      Citations:    Fields:    Translation:Humans
    304. Paterson PY, Semo R, Blumenschein G, Swelstad J. Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. Clin Exp Immunol. 1971 Nov; 9(5):595-602. PMID: 4947556; PMCID: PMC1713066.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    305. Grant JA, Blumenschein GR, Buckley CE. Familial paraproteinemia. Arch Intern Med. 1971 Sep; 128(3):427-31. PMID: 4106045.
      Citations: 3     Fields:    Translation:HumansCells
    306. Woods R, Blumenschein GR, Terry WD. A new type of human gamma heavy chain disease protein: immunochemical and physical characteristics. Immunochemistry. 1970 Apr; 7(4):373-81. PMID: 4194087.
      Citations: 5     Fields:    Translation:HumansAnimals
    307. Blumenschein GR, Moloney JB. Quantitative dose-response relationships of murine sarcoma virus (Moloney) in BALB/c mice. J Natl Cancer Inst. 1969 Jan; 42(1):123-33. PMID: 5765223.
      Citations: 7     Fields:    Translation:AnimalsCells
    308. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 26:894-901.
    309. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    310. Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy. Journal of Clinical Oncology. 34:e34-e37.
    311. Immunotherapy for non-small cell lung cancer. Chinese Journal of Lung Cancer. 16:9-20.
    312. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 1.
    313. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Translational Lung Cancer Research. 1:179-193.
    314. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head and Neck. 37:644-649.
    315. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    BLUMENSCHEIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (656)
    Explore
    _
    Co-Authors (183)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _